Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a leader in autoimmune diagnostics, providing specialized testing solutions through its CLIA-certified laboratory and proprietary AVISE® platform. This page serves as the definitive source for verified news and announcements related to the company’s advancements in rheumatology diagnostics, financial developments, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study outcomes, and operational achievements. Our curated collection includes earnings reports, partnership announcements, and insights into biomarker research that drives Exagen’s industry-leading tests for conditions like lupus and rheumatoid arthritis.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and medical accuracy. Bookmark this page to efficiently track Exagen’s progress in improving diagnostic clarity for autoimmune diseases while staying informed about its role in advancing personalized medicine.
Exagen Inc. (Nasdaq: XGN) plans to release its financial results for Q1 2023 on May 15, 2023, after market close. The conference call to discuss these results will be hosted by CEO John Aballi and CFO Kamal Adawi at 4:30 PM ET. Analysts and investors can join the call by dialing the provided numbers or accessing it via the Exagen investor relations website. A replay will be available until May 29, 2023. Exagen specializes in autoimmune diagnostic solutions and aims to enhance precision medicine through its AVISE® testing products.
Exagen Inc. (Nasdaq: XGN) announced fourth quarter and full year 2022 financial results, achieving a record 135,210 AVISE® CTD tests. Total revenue for 2022 was $45.6 million, down from $48.3 million in 2021. The fourth quarter saw revenues of $12.8 million, slightly up from $12.7 million year-over-year. However, gross margin dropped to 50.9% from 61.1% due to increased costs. Operating expenses rose to $27.3 million, influenced by a one-time goodwill impairment and severance charges. The net loss for 2022 was $47.4 million, compared to a loss of $26.9 million in 2021. The company raised its revenue guidance for the first quarter of 2023 to $9.2-$9.7 million.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the fourth quarter and full year ended December 31, 2022, on March 20, 2023, after market close. CEO John Aballi and CFO Kamal Adawi will discuss these results in a conference call at 4:30 PM ET. Interested listeners can dial (201) 389-0918 for U.S. participants or (877) 407-0890 for international attendees. A replay will be available until April 3, 2023. Exagen specializes in autoimmune diagnostic testing solutions, focusing on precision medicine to assist patients and healthcare providers.
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune testing solutions, announced its participation in two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference from March 6-8, where CEO John Aballi and CFO Kamal Adawi will engage in a fireside chat on March 6 at 10:30 AM ET. The second is a virtual participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21-22, with a separate chat on March 22 at 1:30 PM ET. Interested parties can access the live webcasts through Exagen’s website.
FAQ
What is the current stock price of Exagen (XGN)?
What is the market cap of Exagen (XGN)?
